【摘要】 目的:研制抗人喉癌/抗血管内皮因子(VEGF)双功能克隆抗体,用于喉癌抗血管生成治疗。方法:采用二次杂交瘤技术制备抗人喉癌/抗VEGF双功能抗体。经酶联免疫吸附试验法和SP法检测喉癌及癌前病患者血清及癌组织中VEGF的含量表达。结果:获得6株分泌抗人喉癌/抗VEGF双功能抗体的杂交瘤,经免疫组化证实与喉癌细胞特异性结合率为93%,而与血管内皮细胞结合率为89%。血清中VEGF含量表达,喉癌组与癌前病组及正常对照组相比差异均显著。IgG亚型鉴定为IgG2aBSAb抗体效价为1∶25600倍(ELISA法)。结论:二次杂交瘤法制备的双功能抗体具有均匀性、可控性、效价高、稳定性好,可用于喉癌抗血管生成治疗,动态检测可作为判断喉癌预后的客观指标。更多还原

【Abstract】 Objective:To study preparation of an anti-human laryngeal carcinoma and anti-VEGF bifunctional clonal antibody, applied to cure antiangiogenesis of laryngeal carcinoma.Methods:The second set hybrid tumor technology was applied to prepare an anti-human laryngeal carcinoma and anti-VEGF bifunctional antibody.Results:We obtained six the second set hybrid tumor of bifunctional antibody. We used immunohistochemist to approve that the specific conjugation rate of bifunctional antibody and laryngeal carcinoma cell was 93%, and vassal endothelium cell was 89%. We used ELISA to approve that IgG sub-type was IgG2aBSAb.Conclusion:The bifunctional antibody prepared by the second set hybrid tumor technology has an uniformity, control and stability, and is applied to cure antiangiogenesis of laryngeal carcinoma, dynamically detection is regarded as objective index of its prognostic.更多还原